OTC OPHTHALMICS FOR EMERGENCY FIRST AID: FDA REQUESTING DATA
OTC OPHTHALMICS FOR EMERGENCY FIRST AID: FDA REQUESTING DATA on the safety and efficacy of ingredients contained in eye-wash drug products used for the emergency first aid treatment of chemical burns of the eye. The agency intends to review data on the ingredients for possible inclusion in the OTC monograph for ophthalmic drug products. The final monograph for ophthalmics, which was issued March 4, 1988, did not address the use of eyewashs for burns because no data were submitted by firms during the rulemaking process. Subsequently, however, the agency received a request for an advisory opinion on the regulatory status of such products. FDA's call for data, published in the Dec. 5 Federal Register, notes that the agency is aware that "a number of these eyewash products for emergency first aid treatment of chemical burns have been marketed prior to the effective date of the ophthalmic drug products final monograph." However, FDA said, "the agency has little data on which to make a determination as to the safety, effectiveness, and labeling of these products." The notice reminds manufacturers that OTC products without approved NDAs may only remain on the market during FDA's review if they were marketed as OTCs prior to Dec. 4, 1975, are not hazardous to health, and do not bear claims for serious conditions that require the attention and supervision of a physician. The agency suggested that manufacturers submit information establishing that currently marketed products are not subject to regulatory action. FDA also emphasized that the current review is not intended for new chemical entities that have not previously been marketed OTC.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: